Preclinical antitumor activity of 5-aza-2′-deoxycytidine agains human head and neck cancer xenografts

Boudewijn J M Braakhuis, Guus A M S van Dongen, Marijke van Walsum, Albert Leyva, Gordon B. Snow

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

The antitumor activity of 5-aza-2′-deoxycytidine (5-aza-dCyd), a nucleoside analog, was established in human head and neck cancer xenografts, transplanted in nude mice. A significant response was noted in 3 of 5 lines, when the drug was injected intraperitoneally at a maximum tolerated dose of 2 mg/kg every four days for three doses. In two most sensitive lines 1 out of 6 tumors regressed completely. The antitumor activity of the drug may depend on the schedule used, as illustrated by the fact that just one of these two lines appeared to be sensitive when treated with low daily doses (0.25 mg/kg). One of the two sensitive lines also responded to the treatment with low daily doses (0.25 mg/kg). In two lines, 5-aza-dCyd showed equal or better antitumor activity when compared to the conventional drugs known to produce remissions in patients with head and neck cancer (cisplatin, methotrexate, bleomycin, 5-fluorouracil and cyclophosphamide). 5-Aza-dCyd is a drug with potential value in the chemotherapeutic treatment of patients with head and neck cancer.

Original languageEnglish
Pages (from-to)299-304
Number of pages6
JournalInvestigational New Drugs
Volume6
Issue number4
DOIs
Publication statusPublished - 1 Dec 1988

Cite this

Braakhuis, Boudewijn J M ; van Dongen, Guus A M S ; van Walsum, Marijke ; Leyva, Albert ; Snow, Gordon B. / Preclinical antitumor activity of 5-aza-2′-deoxycytidine agains human head and neck cancer xenografts. In: Investigational New Drugs. 1988 ; Vol. 6, No. 4. pp. 299-304.
@article{b9bd4b795a814d28834031f1f89d3082,
title = "Preclinical antitumor activity of 5-aza-2′-deoxycytidine agains human head and neck cancer xenografts",
abstract = "The antitumor activity of 5-aza-2′-deoxycytidine (5-aza-dCyd), a nucleoside analog, was established in human head and neck cancer xenografts, transplanted in nude mice. A significant response was noted in 3 of 5 lines, when the drug was injected intraperitoneally at a maximum tolerated dose of 2 mg/kg every four days for three doses. In two most sensitive lines 1 out of 6 tumors regressed completely. The antitumor activity of the drug may depend on the schedule used, as illustrated by the fact that just one of these two lines appeared to be sensitive when treated with low daily doses (0.25 mg/kg). One of the two sensitive lines also responded to the treatment with low daily doses (0.25 mg/kg). In two lines, 5-aza-dCyd showed equal or better antitumor activity when compared to the conventional drugs known to produce remissions in patients with head and neck cancer (cisplatin, methotrexate, bleomycin, 5-fluorouracil and cyclophosphamide). 5-Aza-dCyd is a drug with potential value in the chemotherapeutic treatment of patients with head and neck cancer.",
keywords = "5-aza-2′-deoxycytidine, chemosensitivity testing, head and neck cancer, xenografts",
author = "Braakhuis, {Boudewijn J M} and {van Dongen}, {Guus A M S} and {van Walsum}, Marijke and Albert Leyva and Snow, {Gordon B.}",
year = "1988",
month = "12",
day = "1",
doi = "10.1007/BF00173648",
language = "English",
volume = "6",
pages = "299--304",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "4",

}

Preclinical antitumor activity of 5-aza-2′-deoxycytidine agains human head and neck cancer xenografts. / Braakhuis, Boudewijn J M; van Dongen, Guus A M S; van Walsum, Marijke; Leyva, Albert; Snow, Gordon B.

In: Investigational New Drugs, Vol. 6, No. 4, 01.12.1988, p. 299-304.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Preclinical antitumor activity of 5-aza-2′-deoxycytidine agains human head and neck cancer xenografts

AU - Braakhuis, Boudewijn J M

AU - van Dongen, Guus A M S

AU - van Walsum, Marijke

AU - Leyva, Albert

AU - Snow, Gordon B.

PY - 1988/12/1

Y1 - 1988/12/1

N2 - The antitumor activity of 5-aza-2′-deoxycytidine (5-aza-dCyd), a nucleoside analog, was established in human head and neck cancer xenografts, transplanted in nude mice. A significant response was noted in 3 of 5 lines, when the drug was injected intraperitoneally at a maximum tolerated dose of 2 mg/kg every four days for three doses. In two most sensitive lines 1 out of 6 tumors regressed completely. The antitumor activity of the drug may depend on the schedule used, as illustrated by the fact that just one of these two lines appeared to be sensitive when treated with low daily doses (0.25 mg/kg). One of the two sensitive lines also responded to the treatment with low daily doses (0.25 mg/kg). In two lines, 5-aza-dCyd showed equal or better antitumor activity when compared to the conventional drugs known to produce remissions in patients with head and neck cancer (cisplatin, methotrexate, bleomycin, 5-fluorouracil and cyclophosphamide). 5-Aza-dCyd is a drug with potential value in the chemotherapeutic treatment of patients with head and neck cancer.

AB - The antitumor activity of 5-aza-2′-deoxycytidine (5-aza-dCyd), a nucleoside analog, was established in human head and neck cancer xenografts, transplanted in nude mice. A significant response was noted in 3 of 5 lines, when the drug was injected intraperitoneally at a maximum tolerated dose of 2 mg/kg every four days for three doses. In two most sensitive lines 1 out of 6 tumors regressed completely. The antitumor activity of the drug may depend on the schedule used, as illustrated by the fact that just one of these two lines appeared to be sensitive when treated with low daily doses (0.25 mg/kg). One of the two sensitive lines also responded to the treatment with low daily doses (0.25 mg/kg). In two lines, 5-aza-dCyd showed equal or better antitumor activity when compared to the conventional drugs known to produce remissions in patients with head and neck cancer (cisplatin, methotrexate, bleomycin, 5-fluorouracil and cyclophosphamide). 5-Aza-dCyd is a drug with potential value in the chemotherapeutic treatment of patients with head and neck cancer.

KW - 5-aza-2′-deoxycytidine

KW - chemosensitivity testing

KW - head and neck cancer

KW - xenografts

UR - http://www.scopus.com/inward/record.url?scp=0024208561&partnerID=8YFLogxK

U2 - 10.1007/BF00173648

DO - 10.1007/BF00173648

M3 - Article

VL - 6

SP - 299

EP - 304

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 4

ER -